(VAHY-uh-lev) (PROH-doo-oh-DOE-puh)

AbbVie, a global biopharmaceutical leader, approached Brandsymbol to develop brand names for their innovative treatment targeting advanced Parkinson’s Disease. Originally referred to as ABBV-951, this non-surgical therapy provides continuous, 24-hour subcutaneous delivery of carbidopa/levodopa. Given its novel approach, the product required distinct naming strategies across different regions, addressing the complexities of regulatory standards and existing trademarks, particularly the established brand DUODOPA in Europe.

Brandsymbol collaborated closely with AbbVie to navigate these challenges, ultimately delivering two unique brand names: Vyalev for the U.S. and Canadian markets and Produodopa for multiple European countries. “Vyalev” leverages the “vya/via” sound for connotations of transport and movement, combined with “lev” to reference foslevodopa. For Europe, the straightforward “Produodopa” emphasizes the prodrug nature of the therapy, aligning with regional naming precedents. Both names were successfully approved, paving the way for a seamless commercial launch and solidifying Brandsymbol’s expertise in global pharmaceutical branding.

For more information, please refer to AbbVie’s press release: AbbVie News.

If you’d like to discuss global naming strategies for your emerging drugs, contact us at Brandsymbol Contact Us.